composed of five subunits encoded by the CYBB, CYBA, NCF1, NCF2, and NCF4 genes, respectively. Pathogenic variants in the CYBB gene cause X-linked recessive CGD (XL-CGD), whereas those involving the other genes lead to autosomal recessive CGD (AR-CGD). 3, 4 However, very little large-scale study on the genetic features of pediatric cases of CGD in China has been conducted to date. Therefore, we conducted this study with large possible population of Chinese pediatric patients to systematically analyze the clinical and genetic features of CGD to better understand its etiology, epidemiology, and progression.
| ME THODS
We retrospectively reviewed patients <18 years old with CGD from Beijing Children's Hospital, Capital Medical University, Beijing, China. CGD was suspected based on its clinical features and was confirmed by dihydrorhodamine-1,2,3 (DHR) flow cytometry assays and/or DNA analysis. 5 The study design was in accordance with the Helsinki Declaration and was approved by the Beijing Children's Hospital Ethics Committee. Informed consent was obtained from the parents or legal guardians of the pediatric participants.
DHR assays were performed as previously described. 6, 7 Stimulation index (SI) was the ratio of geometric mean of DHR from phorbol-12-myristate-14-acetate (PMA)-stimulated samples to that from unstimulated samples of the same individual. Genomic DNA was extracted from peripheral blood cells using Mini Blood Kit (Qiagen, Duesseldorf, Germany). Genes relevant to CGD (ie, CYBB, CYBA, NCF1, and NCF2) were amplified using a PCR Kit (Qiagen, Duesseldorf, Germany), followed by sequence analysis. The entire DNA sequences, including bordering intron sequences, of CYBB, CYBA, and NCF2 were analyzed. However, for NCF1, we only sequenced exon 2, to detect patients with c.75_76delGT. The primers of all the genes are available in the Supplementary Material.
All data were analyzed using SPSS ver. 19 .0 (International Business Machines Corporation, Chicago, IL, USA). Continuous data were expressed as the mean ± standard deviation or range.
Proportions were compared using the chi-square or Fisher's exact test, and continuous variables within two groups were compared using the independent t test. All tests were two-tailed, and P < 0.05 was considered statistically significant.
| RE SULTS

| Demographic features
A total of 159 pediatric CGD patients were enrolled in this study, with a male-to-female ratio of 7 Additionally, in our study, 132 pediatric patients had XL-CGD and 15 with AR-CGD. Most of the pediatric patients with XL-CGD were males, whereas the majority of pediatric patients with AR-GCD were females (P < 0.05; Table 1 ). The average age at diagnosis for those with XL-CGD (2.1 ± 2.5 years) was younger than those with AR-CGD (4.1 ± 4.6 years; t = −2.7, P = 0.007). The mean age of clinical onset in XL-CGD (6.3 ± 13.3 months) was earlier than that in AR patients (16.9 ± 34.2 months; t = −2.2, P = 0.025).
| Clinical features
In our study, the most common initial infection site and common invasion site (manifesting with pneumonia) were the lungs (Table 1) .
Aspergillus infections were relatively common, and the second one was Tuberculosis (TB) infection. Eight pediatric patients were diagnosed with disseminated TB disease. The lymph nodes, liver, and skin were more readily invaded in the CYBB mutant groups than in the non-CYBB mutant groups (P < 0.05). Perianal abscess was another common clinical manifestation in CGD pediatric patients, accounting for 26 
Key Message
Chronic granulomatous disease (CGD) is a rare disease in China, and very little large-scale studies have been conducted to date. We conducted this study to describe the clinical and genetic features of pediatric CGD in China during the past ten years in order to provide scientific and useful data for this disease. A total of 159 pediatric patients with CGD were enrolled. We found in China CGD patients were often diagnosed at a later age and thus the mortality rate is relatively high. The prevalence and the severity of disease in XL-CGD is higher than AR-CGD. For male Chinese patients with recurrent infection within one year of age or with BCG disease, CGD should be considered. groups, no difference in abnormal responses to BCG vaccination was observed in these two groups (P > 0.05). The other symptoms are shown in Table 1 .
| Laboratory findings
A total of 128 pediatric patients underwent blood testing. Among these, 84% (107/128) of the patients had leukocytosis with neutrophils predominant, of which 31% (33/107) of the patients had WBC counts >20 × 10 9 /L. No cases of neutropenia were identified.
A total of 116 (91%) pediatric patients had an elevated C-reactive protein (CRP) levels, and 83% (75/90) showed increased erythrocyte sedimentation rate (ESR). Meanwhile, decreased hemoglobin levels, ranging from 44 to 90 g/L, were observed in 39.8% (51/128) of the patients. There was no difference in the prevalence of leukocytosis, increased CRP and ESR, and decreased hemoglobin between the XL-CGD and AR-CGD groups (P > 0.05). Furthermore, five pediatric patients had elevated eosinophil counts, ranging from 8.3% to 19.1%, and two cases had thrombocytopenia (from 68 × 10 9 /L to 88 × 10 9 /L), although these returned to normal once the infection was controlled. them had a homozygous mutation and three had compound heterozygous mutations (Table 3 ).
| Genetic analysis
| Treatment and outcomes
In our study, all CGD patients were advised to receive prophylactic F I G U R E 2 Survival rate of CGD pediatric patients in different groups. A, Survival curves for pediatric patients with CGD; B, Survival curves for male and female group. Significant differences were observed (P = 0.0153); C, Survival curves for CYBB and non-CYBB groups. Significant differences were observed (P = 0.0184); and D, Survival curves for HSCT and non-HSCT groups. Significant differences were observed (P = 0.0137) of cases were diagnosed nearly within the past 5 years.
| D ISCUSS I ON
Chronic granulomatous disease patients were predominantly male and usually present symptoms at an early age. In our study, the median age of clinical onset in CGD patients was 1.4 months, but the age of CGD diagnosis in China is often later. However, in the United States and Europe, the age of onset symptoms is older than in China, 8, 9 which may be because Chinese children receive BCG vaccination routinely right after birth. Additionally, we found that the age of XL-CGD clinical onset was younger than that of AR-CGD, which is similar to the findings of earlier study. 10 In addition, previous studies have shown that 30%-40% of CGD patients have a family history of CGD, whereas in our study, only 21% had a positive family history of CGD. In our study, nearly 64% of the CGD pediatric patients suffered from abnormal responses to BCG vaccination, which was similar to Zhou et al's study. 11 They reported a cohort of 169 CGD patients exposed to BCG vaccination and showed a high incidence (59%) of BCG infection in China. 11 In Hong Kong and Iran, 47% and 56% of CGD patients develop BCGitis. 12, 13 Apart from CGD, BCG infections are reported in other primary immunodeficiency diseases (PID), including severe combined immunodeficiency syndrome (SCID), Mendelian susceptibility to mycobacterial diseases (MSMD), and X-linked hyper-IgM syndrome (XHIM). 14, 15 For this reason, there is restriction on the BCG vaccination for the PID patients and newborns with a family history of these PID.
In our study, lungs were the most common invasion sites (manifested as pneumonia) during the course of CGD. However, the prevalence of pneumonia among CGD patients in some European countries is lower (eg, Italy, 47%). Aspergillus was the most common pathogen in our study. Previous studies have also reported that
Aspergillus was the most common pathogen in CGD patients with pneumonia, with an incidence of 41% in the United States and 18% in Europe. 3, 8 TB is also another common pathogen of Chinese CGD patients. In the United States and Israel, deep abscesses, including liver, spleen, and brain, or pulmonary abscesses are the major manifestations, accounting for 46% to 76% of the symptoms, which differs from the results of this study. 3, 9 In Europe, the lungs (66% of patients), skin (53%), lymph nodes (50%), gastrointestinal tract (48%), and liver (32%) were the most frequently infected sites. 8 Perianal abscesses are a typical symptom of CGD patients; however, this is non-specific, and in our study, the rate was higher than that of the United Kingdom and Ireland (15%), Italy (8%), and Europe (21%). 8, 16 Bortoletto et al 3 analyzed CGD patients and reported that XL-CGD has a significantly higher rate of perirectal abscess, gastric obstruction, and urinary tract obstruction. However, we did not obtain similar results, which might be because of the smaller size of the study population. Further investigations should thus be performed.
Additionally, we found one patient with inflammatory bowel disease (IBD) similar to that reported by a previous study and pointed out that the prevalence of CGD-IBD increases with age, the symptoms are usually mild, and patients show good responses to treatment. 17 In this study, we found that most CGD patients have hypergammaglobulinemia. Similar results were also demonstrated by the previous studies. [18] [19] [20] The positive detection rate of pathogens was low in our study, which was similar to that observed in a previous study. 8 This might be due to previous long-term antibiotic/antifungal prophylactic therapy. Catalase-positive bacteria and fungi such as staphylococci, Serratia, Burkholderia, and Aspergillus are the major pathogens in CGD patients. 21, 22 In our study, Aspergillus and TB were the two most common pathogens, whereas in the United States, the most common pathogens were Staphylococcus aureus, Serratia marcescens, Burkholderia cepacia, Nocardia, and Aspergillus. 3 Burkholderia cepacia was not common in our study, but the patient with this pathogen infection showed poor prognosis.
Previous studies have shown that nearly 70% of the patients with CGD harbored CYBB pathogenic variants (ie, XL-CGD), 3, 8 whereas in our study, 89% of the patients carried CYBB variants. However, studies conducted in Arab/North African countries and Turkey showed that AR-CGD accounts for 71% and 67% of the cases, respectively, more common than XL-CGD. 8, 12 This difference in prevalence rates may be attributable to the fact that consanguineous marriage is a common practice in these countries. To date, we detected CYBB variants in CGD patients, mostly involving exons 7 and 9, similar to that of previous studies. 8, 23 Mutation analysis remains an important tool for genetic counseling and prenatal diagnosis. 24 Except for the CYBB variant, a previous study has shown that there are at least three types of AR-CGD, which include NCF1 (20%), NCF2 (5%), and CYBA (5%). 8 However, in our study, we found AR-CGD is rare in Chinese pediatric patients, and CYBA is more common than the other two types. In NCF1, we only searched for the most common mutation (a GT homozygous deletion), and four patients had this mutation. The mutation in six CGD patients was not determined in our study, but we lost the chance to do further analysis.
The first study of CGD demonstrated a mortality rate of >50% by age 6 and almost 65% mortality by age 7. 25 With advances in medicine, decrease in mortality rate has been achieved. 3, 26 A recent study reported a median survival of 25 years in 50% of cases after diagnosis. 16 In Europe, the median life expectancy of CGD is relatively high (37.8 years for XL-CGD patients and 49.6 years for AR-CGD patients). 8 However, in our study, the mortality rate of Chinese pediatric CGD patients is 43%, and the median age of death is 2 years. By age 12, the mortality rate is 50%. Additionally, we found that the mortality rate in patients with XL-CGD, males, or non-HSCT treatment was higher than those with AR-CGD, females, or HSCT treatment, respectively. A previous study also demonstrated a higher mortality rate among the XL-CGD patients than in AR-CGD patients. 8 Antibacterial prophylaxis and immunotherapy with interferon-γ are helpful in reducing the frequency of infection in CGD patients. 9, 27 However, Martire et al demonstrated that IFN-γ treatment did not reduce the incidence of infections. 16 In our study, all patients were recommended for prophylaxis using these methods. Unfortunately, not all of the patients followed this recommendation for different reasons. BCG vaccine-induced disease is the risk factor for CGD patients. Timely and effective treatment is very important. A previous study showed recombinant human IFN-gamma treatment together with anti-TB drugs could provide better control of BCGosis. 28 In our study, we treated these patients with IFN-gamma and anti-TB drugs (isoniazid, rifampicin, and ethambutol), but because of very few follow-up patients, we did not get significant statistics.
Additionally, we suggested to treat vaccinated CGD patients with anti-TB drugs in our study, even though there were no symptoms. But no guidelines were demonstrated for the treatment method of these patients until now. It still needs further study. Åhlin and Fasth 29 pointed out that bone marrow or stem cell transplantation could reduce mortality of CGD patients. In our study, 25 patients received transplantation, and 22 of them lived a longer life. However, some patients also might die of GVHD and infection after transplantation. Gene therapy may be another curative option. This can correct CGD by gene transfer, and now, some clinical trials have provided some insights into the application of gene therapy for CGD patients. 
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